IN2012DN00303A - - Google Patents

Info

Publication number
IN2012DN00303A
IN2012DN00303A IN303DEN2012A IN2012DN00303A IN 2012DN00303 A IN2012DN00303 A IN 2012DN00303A IN 303DEN2012 A IN303DEN2012 A IN 303DEN2012A IN 2012DN00303 A IN2012DN00303 A IN 2012DN00303A
Authority
IN
India
Prior art keywords
avß5
integrin
treating
preventing
sepsis
Prior art date
Application number
Other languages
English (en)
Inventor
Dean Sheppard
George Su
Amba Atakilit
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of IN2012DN00303A publication Critical patent/IN2012DN00303A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN303DEN2012 2009-07-24 2010-07-26 IN2012DN00303A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22841609P 2009-07-24 2009-07-24
PCT/US2010/043211 WO2011011775A1 (en) 2009-07-24 2010-07-26 Methods and compositions for treating and preventing disease associated with avb5 integrin

Publications (1)

Publication Number Publication Date
IN2012DN00303A true IN2012DN00303A (ko) 2015-05-08

Family

ID=43499449

Family Applications (1)

Application Number Title Priority Date Filing Date
IN303DEN2012 IN2012DN00303A (ko) 2009-07-24 2010-07-26

Country Status (11)

Country Link
US (1) US10087252B2 (ko)
EP (1) EP2456460A4 (ko)
JP (1) JP5755647B2 (ko)
KR (1) KR101752515B1 (ko)
CN (1) CN102481347A (ko)
AU (1) AU2010275367B2 (ko)
BR (1) BR112012001463A2 (ko)
CA (1) CA2767409C (ko)
IL (1) IL217406A (ko)
IN (1) IN2012DN00303A (ko)
WO (1) WO2011011775A1 (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201215414D0 (en) * 2012-08-30 2012-10-17 Isis Innovation Composition and use
MX2015011670A (es) * 2013-03-15 2016-03-31 Biogen Ma Inc Tratamiento y prevencion de lesion renal aguda usando anticuerpos anti-alfa v beta 5.
JP2017534252A (ja) * 2014-09-12 2017-11-24 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． ヒト化抗アルファｖベータ５抗体及びその使用
CN109476632A (zh) * 2016-07-05 2019-03-15 洛克菲勒大学 四氢萘啶戊酰胺整联蛋白拮抗剂

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
AU606320B2 (en) 1985-11-01 1991-02-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
IE66205B1 (en) 1990-06-14 1995-12-13 Paul A Bartlett Polypeptide analogs
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
US5527679A (en) 1991-05-01 1996-06-18 Dana Farber Cancer Institute β5 protein and DNA encoding the same
DE4142366A1 (de) 1991-07-15 1993-06-24 Thomae Gmbh Dr K Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE4123341A1 (de) 1991-07-15 1993-01-21 Thomae Gmbh Dr K Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US5777085A (en) 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
US6291196B1 (en) 1992-01-31 2001-09-18 Research Corporation Technologies, Inc. Melanoma and prostate cancer specific antibodies for immunodetection and immunotherapy
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5593853A (en) 1994-02-09 1997-01-14 Martek Corporation Generation and screening of synthetic drug libraries
US5539083A (en) 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
US5525735A (en) 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5549974A (en) 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
US5780426A (en) 1995-06-07 1998-07-14 Ixsys, Incorporated Fivemer cyclic peptide inhibitors of diseases involving αv β3
US5569588A (en) 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
US7053041B1 (en) 1996-05-31 2006-05-30 The Scripps Research Institute Methods and compositions useful for inhibition of αvβ5mediated angiogenesis
UA60311C2 (uk) 1996-10-02 2003-10-15 Смітклайн Бічам Корпорейшн Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція
CO4920232A1 (es) 1997-01-08 2000-05-29 Smithkline Beecham Corp Acidos aceticos dibenzo [a,d] cicloheptano con actividad antagonista del receptor de vitronectin
AR013269A1 (es) 1997-08-04 2000-12-13 Scras Producto que contiene por lo menos un rna de doble filamento combinado con por lo menos un agente anti-viral, para la utilizacion terapeutica en eltratamiento de una enfermedad viral, en especial de la hepatitis viral
EE04752B1 (et) 1997-08-08 2006-12-15 The Regents Of The University Of California Monoklonaalne antikeha, seda tootev hübridoom ja antikeha kasutamine
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
GB9827152D0 (en) 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
DE19842415A1 (de) 1998-09-16 2000-03-23 Merck Patent Gmbh Pharmazeutische Zubereitung
JP2002531466A (ja) 1998-12-01 2002-09-24 プロテイン デザイン ラブス， インコーポレイテッド γ−インターフェロンに対するヒト化抗体
WO2000044914A1 (en) 1999-01-28 2000-08-03 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
ATE300531T1 (de) 1999-09-29 2005-08-15 Ortho Mcneil Pharm Inc Isonipecotamide zur behandlung von integrin vermittelten störungen
AU1086501A (en) 1999-10-15 2001-04-30 Carnegie Institution Of Washington Rna interference pathway genes as tools for targeted genetic interference
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
WO2001053297A1 (en) 2000-01-20 2001-07-26 Merck & Co., Inc. Alpha v integrin receptor antagonists
EP1254116A4 (en) 2000-01-24 2003-04-23 Merck & Co Inc ALPHA V INTEGRIN RECEPTOR ANTAGONISTS
JP4039856B2 (ja) 2000-02-03 2008-01-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 インテグリン発現阻害剤
WO2001078790A2 (en) 2000-04-18 2001-10-25 Edema Clearance, Inc. GENE THERAPHY FOR PULMONARY EDEMA USING ADENOVIRUS VECTORS ENCODING A β2ADRENERGIC RECEPTOR GENE
JP2004525069A (ja) 2000-06-15 2004-08-19 ファルマシア・コーポレーション インテグリン受容体アンタゴニストとしてのシクロアルキルアルカン酸
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
US7163681B2 (en) 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
DE10041423A1 (de) 2000-08-23 2002-03-07 Merck Patent Gmbh Biphenylderivate
US20020072500A1 (en) 2000-09-27 2002-06-13 Thomas Rogers Hydroxy acid integrin antagonists
WO2002040505A2 (en) 2000-10-24 2002-05-23 Merck & Co., Inc. Dibenzoxazepine alpha v integrin receptor antagonist
CA2433680A1 (en) 2000-12-28 2002-08-01 Gregory M Arndt Double-stranded rna-mediated gene suppression
WO2002081627A2 (en) 2001-04-04 2002-10-17 Allergan, Inc. Methods of screening and using inhibitors of angiogenesis
DE60208186T2 (de) 2001-04-09 2006-08-24 Ortho-Mcneil Pharmaceutical Research Inc. Chinazolin- und chinazolinähnliche verbindungen zur behandlung von integrin-vermittelten erkrankungen
US20040019206A1 (en) 2001-09-27 2004-01-29 Peter Ruminiski Lactone integrin antagonists
US7923454B2 (en) 2002-05-17 2011-04-12 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
JP4554364B2 (ja) 2002-08-16 2010-09-29 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ インテグリンと選択的に結合するピペリジニル化合物
JP5223072B2 (ja) * 2004-04-02 2013-06-26 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ａｖβ５インテグリンに関連のある疾患を治療および予防するための方法および組成物
CA2729684A1 (en) * 2008-12-12 2010-06-17 University Of Utah Research Foundation Compositions and methods for promoting vascular barrier function and treating pulmonary fibrosis
JO3421B1 (ar) 2011-06-20 2019-10-20 H Lundbeck As طريقة لإعطاء 1-((1ار.3س)-6-كلورو-3-فينيل-اندان-1-ايل)-1.2.2-ترايميثيل- بيبيرازين واملاجها لمعالجة انفصام الشخصية
MX2015011670A (es) * 2013-03-15 2016-03-31 Biogen Ma Inc Tratamiento y prevencion de lesion renal aguda usando anticuerpos anti-alfa v beta 5.
JP2017534252A (ja) * 2014-09-12 2017-11-24 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． ヒト化抗アルファｖベータ５抗体及びその使用

Also Published As

Publication number Publication date
US20120328604A1 (en) 2012-12-27
CA2767409A1 (en) 2011-01-27
IL217406A (en) 2016-02-29
EP2456460A1 (en) 2012-05-30
KR20120052312A (ko) 2012-05-23
IL217406A0 (en) 2012-02-29
EP2456460A4 (en) 2013-02-20
CN102481347A (zh) 2012-05-30
US10087252B2 (en) 2018-10-02
AU2010275367B2 (en) 2015-09-03
JP5755647B2 (ja) 2015-07-29
WO2011011775A1 (en) 2011-01-27
AU2010275367A1 (en) 2012-02-02
CA2767409C (en) 2018-10-30
JP2013500269A (ja) 2013-01-07
BR112012001463A2 (pt) 2016-03-15
KR101752515B1 (ko) 2017-06-29

Similar Documents

Publication Publication Date Title
IL261900A (en) Humanized antibodies against liv-1, preparations containing them and their uses
CY1122978T1 (el) Αντισωματα εναντι-vla-4
TN2010000213A1 (en) Wise binding antibodies and epitopes
IL212099A0 (en) Cross-species specific psmaxcd3 bispecific single chain antibodies, compositions comprising the same and uses thereof
IL212100A0 (en) Cross-species-specific spcaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxcd3, igf-irxcd3 or fapalphaxcd3 bispecific single chain antibodies, compositions comprising the same and uses thereof
PH12014501108A1 (en) Anti-il-36r antibodies
IL252154A0 (en) Antibodies against dr5, preparations containing them and their uses
MX2013005015A (es) Anticuerpos anti-il-23.
MX2010005682A (es) Anticuerpos bivalentes, biespecificos.
MX2010005888A (es) Anticuerpos bivalentes biespecificos.
MX2010006396A (es) Anticuerpos bivalentes, biespecificos.
UA100874C2 (en) Bivalent bispecific antibodies
WO2013006490A3 (en) Antibodies that specifically bind to tim3
IL216014A0 (en) Antibodies immunorective with heregulin-her3 complexes, compositions comprising the same and uses thereof
MX2014008102A (es) Inmunoglobulinas de dominio variable dual contra receptores.
EA201291039A1 (ru) Антитела, связывающие cd27 человека, и их применение
WO2012019024A3 (en) Her3-binding molecules and immunoconjugates thereof
IN2012DN02046A (ko)
BR112013007229A2 (pt) ''composição,mistura e processo''.
EA201390575A1 (ru) Неантагонистические egfr-связывающие молекулы и их иммуноконъюгаты
IL212066A (en) 4cxcr antibodies, preparations containing them, processes for their production and selection and use for cancer treatment
ZA201102081B (en) Engineered anti0il-13 antibodies,compositions,methods and uses
EP2354161A4 (en) ANTI-NR10 ANTIBODIES AND CORRESPONDING USE
IL219827A0 (en) Lyophilization methods, compositions, and kits
WO2011103490A3 (en) INTEGRIN αVβ8 NEUTRALIZING ANTIBODY